Biocryst Pharmaceuticals (BCRX) Receivables - Net (2010 - 2026)

Biocryst Pharmaceuticals' Receivables - Net history runs 17 years deep, the most recent figure standing at $109.3 million for Q1 2026.

• Quarterly Receivables - Net rose 17.0% year-over-year to $109.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $109.3 million (up 17.0% YoY) and the FY2025 annual result came in at $106.8 million, up 35.09% from the prior year.
• Receivables - Net was $109.3 million for Q1 2026 at Biocryst Pharmaceuticals, up from $106.8 million in the prior quarter.
• Across five years, Receivables - Net topped out at $109.3 million in Q1 2026 and bottomed at $36.4 million in Q1 2022.
• A 5-year average of $67.6 million and a median of $60.6 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net surged 98.06% — and 2026, when it advanced 17.0%.
• Biocryst Pharmaceuticals' Receivables - Net stood at $41.5 million in 2022, then surged by 37.2% to $57.0 million in 2023, then surged by 33.95% to $76.3 million in 2024, then soared by 40.03% to $106.8 million in 2025, then grew by 2.3% to $109.3 million in 2026.
• Business Quant data shows BCRX's Receivables - Net at $109.3 million in Q1 2026, $106.8 million in Q4 2025, and $91.3 million in Q3 2025.